Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients. (10th February 2013)

• Record Type: Journal Article
• Authors: Barakat, Lolwa; Jayyousi, Amin; Bener, Abdulbari; Zuby, Bilal; Zirie, Mahmoud
• Other Names: Kumai T. Academic Editor.; Vree T. B. Academic Editor.
• Is Part Of: ISRN pharmacology. Volume 2013(2013)
• Publication Date: 2013-02-10
• Subjects: Pharmacology -- Periodicals; Pharmacological Phenomena; Pharmacology; Pharmacology; Electronic journals; Periodical; Periodicals; Fulltext; Internet Resources; Periodicals; 615.1
• DOI: 10.1155/2013/146579
• Languages: English
• ISSNs: 2090-5165

Abstract

Abstract : Objectives . To investigate the efficacy and the safety of the three most commonly prescribed statins (rosuvastatin, atorvastatin, and pravastatin) for managing dyslipidemia among diabetic patients in Qatar. Subjects and Methods . This retrospective observational population-based study included 350 consecutive diabetes patients who were diagnosed with dyslipidemia and prescribed any of the indicated statins between September 2005 and September 2009. Data was collected by review of the Pharmacy Database, the Electronic Medical Records Database (EMR viewer), and the Patient's Medical Records. Comparisons of lipid profile measurements at baseline and at first- and second-year intervals were taken. Results . Rosuvastatin (10 mg) was the most effective at reducing LDL-C (29.03%). Atorvastatin reduced LDL-C the most at a dose of 40 mg (22.8%), and pravastatin reduced LDL-C the most at a dose of 20 mg (20.3%). All three statins were safe in relation to muscular and hepatic functions. In relation to renal function, atorvastatin was the safest statin as it resulted in the least number of patients at the end of 2 years of treatment with the new onset of microalbuminuria (10.9%) followed by rosuvastatin (14.3%) and then pravastatin (26.6%). Conclusion . In the Qatari context, the most effective statin at reducing LDL-C was rosuvastatin 10 mg. Atorvastatin was the safest statin in relation to renal function. Future large-scale prospective studies are needed to confirm these results.